8-K filing — Intellia Therapeutics, Inc. (NTLA)
Filed: 2026-09-08 AccNo: 0001193125-26-385194 Size: 257 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Stocks · News reference
Intellia Therapeutics Announces FDA Acceptance For Its Biologics License Application For Ionvo-Z; FDA Sets March 10, 2027, As PDUFA Date
Intellia Therapeutics, Inc. (Nasdaq: NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced the U.S. Food and Drug
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Intellia Therapeutics Secures Non-Dilutive Debt Facility with OrbiMed for up to $400 Million
Intellia Therapeutics announced a $400 million non-dilutive senior secured term loan facility with OrbiMed, consisting of $75 million upfront and $325 million tied to milestones. The financing provides strategic flexibility as the company advances toward U.S. approval and commercial launch of lonvo-z for hereditary angioedema treatment, while also supporting advancement of nexiguran ziclumeran in transthyretin amyloidosis.
Intellia Therapeutics Enters Into $400M Non-Dilutive Senior Secured Term Loan Facility With OrbiMed
Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading biopharmaceutical company focused on revolutionizing medicine leveraging CRISPR gene editing and other core technologies, today announced that it has entered into a